FMC-220 is the second potential first-in-class program to advance from the platform, following FMC-376, a dual ON/OFF KRASG12C inhibitor currently in clinical development. Presentation details follow: ...

FMC-376 is a potential best-in-class therapy designed to completely block both forms of the KRAS mutation to overcome the lack of response and resistance seen with single-acting KRAS G12C inhibitors.

Frontier Medicines Unveils New Preclinical Data for FMC-220, a First-in-Class Covalent p53 Y220C Activator, at AACR 2025 Frontier Medicines Mon, Apr 28, 2025, 12:30 PM 3 min read ...

Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumorsFMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

Frontier Medicines Unveils New Preclinical Data For FMC-220, A First-In-Class Covalent P53 Y220C ... The company plans to file an Investigational New Drug (IND) application for FMC-220 in the ...

FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies, FMC-220 demonstrated unprecedented ...

Frontier Medicines. FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches. In preclinical studies, FMC-220 ...

This innovative drug candidate leverages a covalent design to deliver prolonged target engagement, ... and move our second development candidate, FMC-220, a first-in-class covalent p53 Y220C activator ...

- Pre-clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone - FMC-376 is broadly active in KRASG12C mutant ...